Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.19 USD
Change Today +0.038 / 3.31%
Volume 41.1K
CDXC On Other Exchanges
As of 8:10 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

chromadex corp (CDXC) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/6/15 - $1.72
52 Week Low
12/16/14 - $0.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CHROMADEX CORP (CDXC)

Related News

No related news articles were found.

chromadex corp (CDXC) Related Businessweek News

No Related Businessweek News Found

chromadex corp (CDXC) Details

ChromaDex Corporation, a natural products company, through its subsidiaries, discovers, acquires, develops, and commercializes proprietary-based ingredient technologies. It offers bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; and supplies reference standards, materials, and kits to conduct quality control of raw materials and consumer products, as well as supplies fine chemicals and phytochemicals. The company also provides a range of contract services ranging from routine contract analysis for the production of dietary supplements, cosmetics, foods, and other natural products to elaborate contract research for clients in these industries; and consulting services in the areas of regulatory support, new ingredient or product development, risk management, and litigation support, as well as product regulatory approval and scientific advisory services. Its products and services in development include Nicotinamide riboside, a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene and caffeine co-crystal that are ingredients for the formulation of energy products; and Anthocyanins, which are secondary plant metabolites for use as candidates in the pharmaceutical, dietary supplement, and food colorants industries. The company markets and sells its products to the nutritional supplement, food and beverage, animal health, cosmetic, and pharmaceutical industries directly in the United States and Canada; and through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. ChromaDex Corporation is headquartered in Irvine, California.

67 Employees
Last Reported Date: 03/19/15

chromadex corp (CDXC) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $305.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $249.2K
Chief Operating Officer
Total Annual Compensation: $179.0K
Compensation as of Fiscal Year 2014.

chromadex corp (CDXC) Key Developments

ChromaDex Corporation Appoints Jeff Baxter as Independent Director

ChromaDex Corp. announced that Jeff Baxter has joined the Company's Board of Directors as an Independent Director. Mr. Baxter, age 53, has served as President and CEO and a Director of VBI Vaccines Inc. since 2009. Previously, he was managing partner for the venture capital firm, The Column Group, where he played a pivotal role in the creation of several biotech companies including Immune Design Corp. Until July of 2006, Mr. Baxter was SVP, R&D Finance and Operations, of GlaxoSmithKline (GSK). In his 19 years of pharma experience at GSK, he has held line management roles in R&D, commercial, manufacturing, Finance and The Office of the CEO. His most recent position in the global R&D organization included responsibility for finance, pipeline resource planning and allocation, business development deal structuring and SROne. He also chaired GSK's R&D Operating Board. Prior to GSK, he worked at Unilever and British American Tobacco. Mr. Baxter was educated at Thames Valley University and is a Fellow of the Chartered Institute of Management Accountants (FCMA).

ChromaDex Corporation Announces Consolidated Earnings Results for the Year Ended January 3, 2015

ChromaDex Corporation announced consolidated earnings results for the year ended January 3, 2015. For the year, net sales were $15,313,179 against $10,160,964 a year ago. This increase was largely due to increased sales in its ingredients business segment, led by its NIAGEN branded nicotinamide riboside. Operating loss was $5,231,349 against $4,386,446 a year ago. Net loss was $5,388,185 against $4,419,525 a year ago. Basic and Diluted loss per common share was $0.05 against $0.04 a year ago. For the year, on Non-GAAP basis, operating loss was $2,314,425 against $3,098,529 a year ago. Net loss was $2,471,261 against $3,131,608 a year ago. Basic and Diluted loss per common share was $0.02 against $0.03 a year ago.

ChromaDex Corporation Presents at Northland Capital Markets 2015 Growth Conference, Mar-18-2015

ChromaDex Corporation Presents at Northland Capital Markets 2015 Growth Conference, Mar-18-2015 . Venue: Omni Berkshire Place Hotel, New York, New York, United States. Speakers: Frank Louis Jaksch, Co-Founder, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CDXC:US $1.19 USD +0.038

CDXC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Eurofins Scientific SE €252.40 EUR +1.00
Sigma-Aldrich Corp $138.89 USD +0.17
View Industry Companies

Industry Analysis


Industry Average

Valuation CDXC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.0x
Price/Book 30.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHROMADEX CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at